- CardioDX files for $86.25M IPO.
- The proposed ticker symbol is CDX. (S-1)
- The company makes Corus CAD, a blood test that determines whether symptoms are due to obstructive coronary artery disease.
- The company's pro forma net loss per share for 2012 was $0.26.
- CDX's sales for the first six months of this year exceeded all of 2012's revenue.